Homes
Public Notices
News
Local news
Editor’s Pick
Pittsburgh
Local Government
Roads, Travel and Traffic
20 Years of Gas Drilling
Regional
U.S. and World
Business
Sports
HS Sports
College Sports
Penguins
Pirates
Steelers
Athlete of the Week
Wild Things
Pony Baseball
Outdoors
Columns
Opinion
Columns
Editorials
Letters to the Editor
Op Eds
Living
Neighbors
School News
Entertainment
Home and Garden
Food
Police Beat
Obituaries
Classifieds
Legal Notices
Sponsored Content
e-Edition
close
Washington County
Greene County
Mon Valley
News
Local news
Police Beat
Pittsburgh
Local Government
Roads, Travel and Traffic
Helping The Helpers
20 Years of Gas Drilling
Regional
U.S. and World
Business News
Sports
High School Sports
College Sports
Penguins
Pirates
Steelers
Wild Things
Pro Sports
Outdoors
Sports Column
Obituaries
Opinion
Columns
Editorials
Letters to the Editor
Op-Ed
Living
Neighbors
Health and Wellness
Entertainment
Home and Garden
Classifieds
Contact Us
Advertise With Us
Customer Service
Contact Information
Submission Forms
Statement of Values
Misc
Special Sections
Events
Sponsored Content
Newsletter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Abbott Laboratories
(NY:
ABT
)
110.83
+1.75 (+1.60%)
Official Closing Price
Updated: 7:00 PM EST, Feb 6, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Abbott Laboratories
< Previous
1
2
3
4
5
6
7
8
9
...
52
53
Next >
The Era of the Titans: Q4 2025 Mega-Deal Surge and the 2026 Economic Map
Today 10:17 EST
As of February 6, 2026, the global financial landscape is still reverberating from a historic tectonic shift that occurred in the final months of last year. In the fourth quarter of 2025, the M&A...
Via
MarketMinute
Topics
Artificial Intelligence
Economy
AbbVie’s Prognosis: The February Dip Looks Like a Buy Signal
↗
February 05, 2026
Via
MarketBeat
Navigating the MedTech Correction: A Deep-Dive into Boston Scientific (NYSE: BSX)
February 05, 2026
February 5, 2026 The medical technology landscape experienced a seismic shift this week as one of its long-standing titans, Boston Scientific (NYSE: BSX), faced a "valuation reset" that has left...
Via
Finterra
Topics
Product Recall
World Trade
Let's take a look at the S&P500 stocks that are experiencing unusual volume in today's session.
↗
January 23, 2026
Via
Chartmill
Greenland Truces and Intel’s Earnings Bruises: Wall Street’s Identity Crisis
↗
January 23, 2026
Via
Chartmill
2 Healthcare Dividend Stocks That are Just What the Doctor Ordered
↗
February 03, 2026
AbbVie and Medtronic have a long history of raising their dividends and continue to have healthy free cash flow for further dividend growth.
Via
The Motley Fool
Topics
Intellectual Property
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Northfield Bancorp Inc. (Nasdaq - NFBK), Coterra Energy Inc. (NYSE - CTRA), Exact Sciences Corporation (Nasdaq – EXAS), Semrush Holdings, Inc. (NYSE – SEMR)
February 03, 2026
From
Brodsky & Smith LLC
Via
GlobeNewswire
The Best Dividend King to Buy With $150
↗
February 02, 2026
The stock is near its 52-week low.
Via
The Motley Fool
Which S&P500 stocks have an unusual volume on Thursday?
↗
January 22, 2026
Via
Chartmill
Abbott Laboratories (NYSE:ABT) Shares Slump on Q4 Revenue Miss and Nutrition Segment Weakness
↗
January 22, 2026
Via
Chartmill
Boston Scientific’s $14.5 Billion Stroke of Genius: Consolidation Heats Up in the Medtech Arms Race
February 02, 2026
In a move that has sent shockwaves through the healthcare sector, Boston Scientific (NYSE:BSX) has announced a definitive agreement to acquire Penumbra (NYSE:PEN) for approximately $14.5 billion. The...
Via
MarketMinute
Topics
Artificial Intelligence
Looking for Passive Income in 2026? 3 Dividend Kings to Buy Hand Over Fist
↗
January 31, 2026
These market giants make great long-term investments.
Via
The Motley Fool
5 Insightful Analyst Questions From Abbott Laboratories’s Q4 Earnings Call
January 29, 2026
Abbott Laboratories ended the fourth quarter with sales growth below Wall Street’s expectations, driven primarily by ongoing challenges in its nutrition segment. Management attributed this...
Via
StockStory
Topics
Earnings
3 Reasons to Buy This Dividend King After Its Steep Sell-Off
↗
January 26, 2026
Investors' reaction to this Dividend King's Q4 revenue miss was overdone.
Via
The Motley Fool
Topics
Earnings
The Best Dividend Stocks to Buy and Hold Forever
↗
January 26, 2026
These stocks offer highly attractive dividends and staying power.
Via
The Motley Fool
Topics
Intellectual Property
Is Abbott’s January Pullback a Good Time to Buy?
↗
January 24, 2026
Via
MarketBeat
Which stocks are moving after the closing bell on Friday?
↗
January 23, 2026
Via
Chartmill
Johnson & Johnson 2026 Outlook: Chasing the $100 Billion Milestone Amidst Legal and Patent Hurdles
January 23, 2026
Following a resilient performance throughout 2025, healthcare giant Johnson & Johnson (NYSE: JNJ) has officially set its sights on a historic milestone for 2026. In its latest earnings report released...
Via
MarketMinute
Topics
Artificial Intelligence
Bankruptcy
Economy
The Software Surge: How 2024’s $25.7 Billion M&A Explosion in Diagnostics Redefined Healthcare
January 23, 2026
The healthcare landscape underwent a seismic shift in 2024, as the industry’s major players pivoted away from traditional hardware toward high-margin diagnostic platforms and artificial intelligence...
Via
MarketMinute
Topics
Artificial Intelligence
Economy
ABT Q4 Deep Dive: Nutrition Weakness and Innovation Shape 2026 Outlook
January 23, 2026
Healthcare product and device company Abbott Laboratories (NYSE:ABT) missed Wall Street’s revenue expectations in Q4 CY2025 as sales rose 4.4% year on year to $11.46 billion. Its non-GAAP profit of...
Via
StockStory
Abbott Laboratories Shares Plunge 10% Following Q4 Revenue Miss and Diagnostics Weakness
January 22, 2026
Abbott Laboratories (NYSE: ABT) saw its stock price tumble by nearly 10% in early trading on January 22, 2026, following the release of its fourth-quarter 2025 financial results. Despite meeting...
Via
MarketMinute
Topics
Economy
These S&P500 stocks are moving in today's session
↗
January 22, 2026
Via
Chartmill
Why Abbott Laboratories (ABT) Shares Are Sliding Today
January 22, 2026
Shares of healthcare product and device company Abbott Laboratories (NYSE:ABT) fell 8.3% in the afternoon session after the company reported fourth-quarter revenue that missed Wall Street's...
Via
StockStory
Top S&P500 movers in Thursday's session
↗
January 22, 2026
Via
Chartmill
Abbott (ABT) Q4 2025 Earnings Call Transcript
↗
January 22, 2026
Abbott (ABT) Q4 2025 Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
World Trade
Abbott Shares Slump as Revenue Miss and Exact Sciences Acquisition Jitters Overshadow Earnings Beat
January 22, 2026
Abbott Laboratories (NYSE: ABT) saw its shares retreat by 5.8% in early trading on Thursday, January 22, 2026, following the release of its fourth-quarter financial results. Despite delivering an...
Via
MarketMinute
Topics
Earnings
Economy
What's going on in today's session: S&P500 gap up and gap down stocks
↗
January 22, 2026
Via
Chartmill
NVE (NVEC) Q3 2026 Earnings Call Transcript
↗
January 22, 2026
NVE (NVEC) Q3 2026 Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
Supply Chain
Abbott Laboratories (NYSE:ABT) Misses Q4 CY2025 Revenue Estimates, Stock Drops
January 22, 2026
Healthcare product and device company Abbott Laboratories (NYSE:ABT) fell short of the markets revenue expectations in Q4 CY2025 as sales rose 4.4% year on year to $11.46 billion. Its non-GAAP profit...
Via
StockStory
Want Decades of Passive Income? 2 Stocks to Buy Right Now.
↗
January 22, 2026
Their dividend streaks speak volumes.
Via
The Motley Fool
Topics
Artificial Intelligence
< Previous
1
2
3
4
5
6
7
8
9
...
52
53
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
Starting at $3.75
/
week.
Subscribe Today